Creating the ideal immunotherapy
Inducing a Broad
Cancer Stem Cells
Vaxil’s Lead Products and Orphan Drug Status
Vaxil believes its immunotherapy platform allows it to target high profile cancer antigens in a uniquely superior manner, all designed to possess the novel advantages described above. Vaxil’s first test of its VaxHit™ platform is its Immucin™; lead immunotherapy product. After completion of a successful Phase-I/II in 15 multiple myeloma cancer patients, Vaxil’s Immucin™ was granted Orphan Drug Status by the FDA and EMA for that indication.
Vaxil’s Lead Immunotherapy Immucin™ Obtains Orphan Drug Status from FDA and EMA